Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2585382 | 1.00 | GLA (0.33) | GLALMNAESR1PGRCHRM2 | |
| SCHEMBL3726007 | 0.73 | ESR1 (0.33) | GLALMNAESR1PGRCHRM2 | |
| SCHEMBL6899350 | 0.73 | ESR1 (0.33) | GLALMNAESR1PGRCHRM2 | |
| SCHEMBL10203319 | 0.73 | ESR1 (0.31) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL14307786 | 0.71 | — | — | |
| SCHEMBL3758701 | 0.71 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL5191282 | 0.71 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL5191287 | 0.71 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL3758703 | 0.71 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL3758711 | 0.71 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018069222-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-04-19 | — | — | WO | disclosed |
| US-20090312559-A1 | CATALYTIC ENANTIOSELECTIVE SILYLATIONS OF SUBSTRATES | NATIONAL INSTITUTES OF HEALTH, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT | 2009-12-17 | — | — | US | disclosed |
| WO-2007082026-A2 | CATALYTIC ENANTIOSELECTIVE SILYLATIONS OF SUBSTRATES | THE TRUSTEES OF BOSTON COLLEGE (US) | 2007-07-19 | — | — | WO | disclosed |
| US-5414173-A | Process of preparing cyclopentadiene and substituted derivatives thereof | THE DOW CHEMICAL COMPANY (US) | 1995-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312559-A1 | CATALYTIC ENANTIOSELECTIVE SILYLATIONS OF SUBSTRATES | LSS, COASY, CYP51A1 | GLA 1348/4885LMNA 1731/4885ESR1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.